natgillin/translations-raw huggingface dataset:
Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on Enbrel continued to improve from month 3 through month 7, while those who received placebo did not improve.
Od svih bolesnika koji su pokazali klinički odgovor 90. dan i ušli u drugi dio ispitivanja neki, koji su ostali na Enbrelu, nastavili su s poboljšanjem od 3. do 7. mjeseca, dok oni koji su primali placebo nisu pokazali poboljšanje.
Of patients with paired liver biopsies, 63% (10/16) of KANUMA-treated patients had improvement in hepatic steatosis (at least  5% reduction) as measured by morphometry compared to 40% (4/10) of placebo patients.
Od bolesnika s uparenim uzorcima biopsije jetre, u 63% (10/16) bolesnika liječenih KANUMOM došlo je poboljšanja jetrene steatoze (najmanje  5% smanjenja) u usporedbi s 40% (4/10) bolesnika koji su primali placebo, mjereno morfometrijom.
of Patients with Response
Bolesnici s odgovorom (%)
of PREZISTA co-administered with
dozom ritonavira i kombinanog lijeka
of PREZISTA co-administered with
dozom ritonavira i kombiniranog lijeka
of PREZISTA co-administered with
dozom ritonavira i kombiniranog lijeka s
Of responders in the pivotal study who completed the extension study, 21 out of 22 (96%) sustained their response to Revestive after an additional 2 years of continuous treatment.
Od bolesnika koji su odgovorili u pivotalnom ispitivanju i koji su završili produžetak ispitivanja, 21 od 22 (96%) održalo je odgovor na lijek Revestive nakon dodatne 2 godine kontinuiranog liječenja.
of rosuvastatin should be
rosuvastatina smije biti 5
of seizures or risk
NAČIN I PUT PRIMJENE LIJEKA
Of the 1,035 patients treated with sofosbuvir/velpatasvir in the three Phase 3 clinical studies, 1,023 patients were included in the analysis of NS5A RAVs; 7 patients were excluded as they neither achieved sustained virologic response (SVR12) nor had virologic failure and 5 additional patients were excluded as NS5A gene sequencing failed.
Od 1035 bolesnika liječenih sofosbuvirom/velpatasvirom u trima kliničkim ispitivanjima faze 3, 1023 bolesnika su bila uključena u analizu NS5A RAV-ova; sedam bolesnika su bila isključena jer nisu postigli održivi virološki odgovor (SVR12) niti su imali virološki neuspjeh te je pet dodatnih bolesnika isključeno zbog neuspjeha sekvencioniranja NS5A gena.
Of the 1,165 patients treated with Picato in the actinic keratosis clinical studies conducted with ingenol mebutate gel, 656 patients (56%) were 65 years and older, while 241 patients (21%) were 75 years and older.
Od 1165 bolesnika liječenih lijekom Picato u ispitivanjima aktiničke keratoze provedenim s gelom ingenol mebutata, 656 bolesnika (56%) bilo je u dobi od 65 godina i starije, dok je 241 bolesnik (21%) bio u dobi 75 godina i stariji.
Of the 1,377 reported bleeds observed in 177 of the 213 patients, 1,244 (90.3%) of the bleeds were resolved with 1-2 infusions of NovoEight.
Od 1377 prijavljenih krvarenja primijećenih u 177 od 213 bolesnika, 1244 (90,3%) slučaja krvarenja riješena su primjenom 1-2 infuzije lijeka NovoEight.
Of the 1108 patients who received any treatment in Trial 1 or Trial 2, 1029 (93%) enrolled and received active treatment in Trial 3.
1108 bolesnika koji su u ispitivanju 1 ili ispitivanju 2 primali bilo koju terapiju, u ispitivanje 3 je uključeno i aktivno liječeno 1029 (93%) bolesnika.
Of the 115 (28%) subjects who experienced one or more episode of hypoglycaemia, 6 subjects experienced a hypoglycaemic seizure on one or more occasion.
Od 115 ( 28%) ispitanika koji su doživjeli jednu ili više epizoda hipoglikemije, 6 ispitanika doživjela su hipoglikemijski napadaj jednom ili više puta.
Of the 12 cases of cystoid macular oedema, 5 were reported as recovered and 7 as ongoing at end of study.
Od 12 slučajeva cistoidnog makularnog edema, kod 5 je zabilježen oporavak, dok je 7 zabilježeno u tijeku na kraju studije.
Of the 12 subjects not randomised in the pivotal study, 6 completed 24 months of treatment with Revestive.
Od 12 ispitanika koji nisu randomizirani u pivotalnom ispitivanju, 6 je završilo 24 mjeseca liječenja lijekom Revestive.
Of the 126 patients, 96 received the recommended dose of ISENTRESS (see section 4.2).
Od 126 bolesnika, 96 ih je primalo preporučenu dozu lijeka ISENTRESS (vidjeti dio 4.2).
Of the 126 patients, 96 received the recommended dose of ISENTRESS.
Od 126 bolesnika 96 ih je primalo preporučenu dozu lijeka ISENTRESS.
Of the 135 (16%) patients with reports of adverse reactions of neutropenia, 13 patients discontinued bosutinib due to neutropenia.
Od 135 (16%) bolesnika s prijavljenim nuspojavama neutropenije, 13 bolesnika prekinulo je liječenje bosutinibom zbog neutropenije.
Of the 138 patients randomised to Cimzia 200 mg every 2 weeks, 92, 68 and 48 had an ACR 20/50/70 response, respectively.
Od 138 bolesnika randomiziranih na 200 mg Cimzije svaka 2 tjedna, njih 92, 68 odnosno 48 imali su ACR 20/50/70 odgovor.
Of the 139 patients included, 128 completed the first 12 months of therapy, with an average treatment time of 3.2 and 4.6 years and a total exposure of 542 patient years.
Od uključenih 139 bolesnika, njih 129 dovršilo je prvih 12 mjeseci liječenja s prosječnim vremenom liječenja od 3,2 i 4,6 godina i ukupnim izlaganjem od 542 bolesničke godine.
Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘lethal’ levels of cyanide in the blood.
Od ukupno 14 bolesnika čije je izlaganje cijanidom bilo uslijed nekog drugog uzroka a ne udisanja dima, 10 ih je preživjelo, uključujući sedam bolesnika sa "smrtonosnim" koncentracijama cijanida u krvi.
Of the 140 subjects who completed the Study 332 114 subjects (81.4%) had entered the Extension phase.
Od 140 ispitanika koji su završili ispitivanje 332, 114 ispitanika (81,4%) ušlo je u fazu produžetka ispitivanja.
Of the 1408 patients who were treated with nivolumab monotherapy 3 mg/kg every 2 weeks and evaluable for the presence of anti-product-antibodies, 155 patients (11.0%) tested positive for treatment-emergent anti-product-antibodies with nine patients (0.6 %) testing positive for neutralising antibodies.
Među 1408 bolesnika liječenih monoterapijom nivolumabom u dozi od 3 mg/kg svaka 2 tjedna u kojih se mogla odrediti prisutnost protutijela na lijek, njih je 155 (11,0%) bilo pozitivno na protutijela na lijek koja su se razvila tijekom liječenja, dok je 9 bolesnika (0,6%) bilo pozitivno na neutralizirajuća protutijela.
Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a median duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
Od 153 bolesnika liječenih zoledronatnom kiselinom i 115 bolesnika liječenih risedronatom, koji su ušli u produljenu studiju praćenja, nakon medijana trajanja praćenja od 3,8 godina, računato od vremena doziranja, stopa bolesnika koji su završili produljeni period praćenja zbog potrebe za ponovnim liječenjem (klinička procjena) bila je veća za risedronat (48 bolesnika ili 41,7%) naspramzoledronske kiseline (11 bolesnika ili 7,2%).
Of the 16 patients with high titres, 15 received immune tolerance induction (ITI).
Od 16 bolesnika s visokim titrom, 15 je primilo liječenje za izazivanje imunološke tolerancije (ITI).
Of the 16 patients with low titres, ITI was started in 10.
Od 16 bolesnika s niskim titrom, 10 je započelo liječenje za izazivanje tolerancije.
Of the 163 ALK-positive NSCLC patients who had received prior treatment with an ALK inhibitor, the median age was 52 years (range: 24-80 years); 86.5% of patients were younger than 65 years.
Kod 163 bolesnika s ALK-pozitivnim NSCLC-om koji su se prethodno liječili ALK inhibitorom, medijan dobi bio je 52 godine (raspon: 24-80 godina); 86,5% bolesnika bilo je mlađe od 65 godina.
Of the 163 patients who were responders at week 24, 139 patients (85.3%) were still responders at week 120.
Od 163 bolesnika koji su odgovorili na liječenje u tjednu 24, 139 bolesnika (85,3%) još uvijek je odgovaralo u 120. tjednu.
Of the 17 ALL patients, 2 achieved a complete remission (12%; CR) and 2 a partial remission (12%; PR) at varying doses.
Od 17 bolesnika s ALL-om, 2 su postigla kompletnu remisiju (12%; KR), a parcijalnu remisiju (12%; PR) pri različitim dozama.
Of the 18 patients with viral resistance development, 13 occurred through Week 48, 3 occurred between Week 48 to Week 96, and 2 occurred between Week 96 to Week 144 of treatment.
Od 18 pacijenata s razvojem virusne rezistencije, 13 ju je razvilo do 48. tjedna, 3 su je razvila između 48. i 96. tjedna, a 2 između 96. i 144. tjedna.
Of the 1826 patients treated with Qutenza in randomized controlled trials, 1089 (59.6%) reported adverse reactions considered related to the medicinal product by the investigator.
Od 1826 bolesnika liječenih Qutenzom u randomiziranim kontroliranim ispitivanjima, 1089 (59,6%) je prijavilo nuspojave koje je ispitivač smatrao povezanima s lijekom.
Of the 190 patients enrolled, 170 completed Period A, 65% (123/190) achieved an ACR Pedi 30 response, and 122 were randomized to Period B. Responses were similar in all subtypes of JIA studied and for patients with or without methotrexate use.
Od 190 bolesnika uključenih u ispitivanje, 170 ih je završilo Razdoblje A, 65% (123/190) njih je postiglo odgovor Ped ACR30, a 122 bolesnika randomizirana su u Razdoblje B. Odgovori su bili slični u svim ispitanim podtipovima JIA-a kao i u bolesnika koji jesu i onih koji nisu uzimali metotreksat.
Of the 190 patients with JIA treated with ORENCIA in this study, one (0.5%) patient discontinued due to non-consecutive infusion reactions, consisting of bronchospasm and urticaria.
Od 190 bolesnika s JIA-om liječenih lijekom ORENCIA u ovom ispitivanju, jedan (0,5%) je bolesnik prekinuo liječenje zbog neuzastopnih infuzijskih reakcija koje su se sastojale od bronhospazma i urtikarije.
Of the 199 randomized patients, the mean age was 58 years, 64% were male, 68% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
Srednja dob 199 randomiziranih bolesnika bila je 58 godina, 64% bili su muškarci, 68% bili su bijelci, a svi su bolesnici imali početno opće stanje prema ECOG-u 0 ili 1.
Of the 2,182 patients with resistance or intolerance to prior imatinib therapy who received dasatinib in clinical studies, 15 (1%) had QTc prolongation reported as an adverse reaction.
Produženja QTc intervala bila su prijavljena kao nuspojava u 15 (1%) od 2182 bolesnika koji ne podnose ili su otporni na prethodnu terapiju imatinibom, a koji su primali dasatinib u kliničkim ispitivanjima.
Of the 2,510 HCV genotype 1 infected subjects who were treated with regimens containing ombitasvir, paritaprevir, and dasabuvir with or without ribavirin (for 8, 12, or 24 weeks) in Phase 2b and 3 clinical trials, a total of 74 subjects (3%) experienced virologic failure (primarily post-treatment relapse).
Od 2510 ispitanika s infekcijom HCV-om genotipa 1 koji su u kliničkim ispitivanjima faze 2b i 3 liječeni režimima koji su sadržavali ombitasvir, paritaprevir i dasabuvir, u kombinaciji s ribavirinom ili bez njega (tijekom 8, 12 ili 24 tjedna), ukupno je njih 74 (3%) doživjelo virološki neuspjeh (prvenstveno relaps nakon liječenja).
Of the 2,532 randomised intention-to-treat (ITT) patients, a total of 59 patients experienced at least one new vertebral fracture, placebo: 42 (3.37) – Preotact: 17 (1.32), p0.001.
Od 2532 randomizirane bolesnice s namjerom liječenja (ITT), njih ukupno 59 imalo je najmanje jedan novi prijelom kralješka, placebo: 42 (3,3%) – Preotact: 17 (1,32%), p=0,001.
Of the 2,712 patients treated, 18% were ≥ 65 years of age, while 5% were ≥ 75 years of age.
Od 2712 liječenih bolesnika, 18% bilo je u dobi od ≥65 godina, dok je 5% bilo u dobi od ≥75 godina.
Of the 208 bleeding episodes treated with Coagadex, 187 bleeding episodes in 15 subjects were evaluated for efficacy.
Od 208 epizoda krvarenja liječenih lijekom Coagadex, 187 epizoda krvarenja kod 15 ispitanika procijenjeno je za djelotvornost.
Of the 215 subjects with sufficient data to determine mutational status, 78.6% (n=169) were classified as RET mutation positive (126 of which were positive for the M918T mutation), and 21.4% (n=46) were classified as RET mutation negative.
Od 215 ispitanikaza koje je postojalo dovoljno podataka za određivanje mutacijskog statusa, njih 78,6% (n=169) su klasificirani kao pozitivni na mutaciju RET-a (od čega je 126 ispitanika bilo pozitivno na mutaciju M918T), a 21,4% (n=46) su klasificirani kao negativni na mutaciju RET-a.
Of the 224 (26%) patients with reports of adverse reactions of anaemia, 5 patients discontinued bosutinib due to anaemia.
Od 224 (26%) bolesnika s prijavljenim nuspojavama anemije, 5 bolesnika prekinulo je liječenje bosutinibom zbog anemije.
Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 showed a statistically significant upward trend in titres, 4 displayed sustained peaks or transient spikes and one patient had both but no clinical symptoms.
Kod ispitivanja razvoja antitijela na proteine jajnih stanica kineskog hrčka (CHO), od 229 liječenih bolesnika, u 3 je uočen trend povišenja titra, što je bilo statistički značajno, u 4 bolesnika povišenje se održalo ili su vrhovi titra bili prolazni, a u jednog bolesnika opaženo je i jedno i drugo ali bez kliničkih simptoma.
Of the 24 patients treated that had the NNRTI-associated K103N substitution pre-existing at baseline in their HIV-1, 22 maintained virologic suppression after switching to FTC/RPV/TDF.
Od 24 liječena bolesnika koji su na početku imali otprije postojeću i s NNRTI povezanu supstituciju K103N kod svojeg HIV-1, kod njih 22 je virus ostao suprimiran nakon prebacivanja na FTC/RPV/TDF.
Of the 26 patients with abnormal liver volumes at pre-treatment baseline, 22 (85%) achieved a normal liver size by the end of the study.
Od 26 bolesnika s povećanom jetrom prije početka liječenja, jetra je postigla normalnu veličinu kod 22 bolesnika (85%) do završetka ispitivanja.
Of the 26 patients without data available in the week 48 window, 7 patients discontinued due to adverse event or death, 16 patients discontinued for other reasons, and 3 patients were missing data but remained on study drug.
Od 26 pacijenata bez dostupnih podataka u 48. tjednom prozoru, 7 pacijenata prekinulo je liječenje zbog nuspojave ili smrti, 16 pacijenata prekinulo je liječenje zbog drugih razloga, a 3 pacijenta nisu imala podatke, ali nastavili su uzimati ispitivani lijek.
Of the 271 patients who received romiplostim in ITP clinical trials, 55 (20%) were age 65 and over, and 27 (10%) were 75 and over.
Od 271 bolesnika koji su primili romiplostim u kliničkim ispitivanjima ITP-a, njih 55 (20%) je imalo 65 godina ili više, a među njima je bilo 27 (10 %) u dobi od 75 godina ili starijih.
Of the 29 genotype 1a patients who qualified for resistance testing, 22/29 (76%) patients harboured one or more NS5A RAVs at positions K24, M28, Q30, L31, S38 and Y93 at failure, while the remaining 7/29 patients had no NS5A RAVs detected at failure.
Od 29 pacijenata s genotipom 1a koji su zadovoljili mjerila za provjeru rezistencije, 22/29 (76 %) pacijenata nosilo je jednu ili više NS5A RAV na položajima K24, M28, Q30, L31, S38 i Y93 u vrijeme virološkog neuspjeha, dok se u preostalih 7/29 pacijenata nije otkrila niti jedna NS5A RAV u vrijeme virološkog neuspjeha.
Of the 29 major surgeries, 24 surgeries (82.8%) required a single pre-operative dose to maintain hemostasis during surgery.
Od 29 većih kirurških zahvata, u 24 kirurška zahvata (82,8%) bila je potrebna jedna doza prije operacije za održavanje hemostaze tijekom kirurškog zahvata.
Of the 29 MCI subjects who had a positive PET scan, 19 (65.5%) were classified clinically as converted to clinical AD after 24 months compared to 0 (0%) of 16 who had a negative scan.
Od 29 bolesnika s blagim oštećenjem kognitivne funkcije u kojih je nalaz PET oslikavanja bio pozitivan, 24 mjeseca kasnije je klinički dijagnosticirana Alzheimerova bolest u njih 19 (65,5%), u usporedbi s 0 (0%) takve dijagnoze od 16 bolesnika s negativnim nalazom PET oslikavanja.
Of the 29 patients described above that were treated in Study CAC-002-01 3 patients discontinued (all due to AEs), and one patient died.
Od 29 prethodno opisanih bolesnika koji su liječeni u sklopu ispitivanja CAC-002-01, 3 bolesnika prekinulo je ispitivanje (svi zbog nuspojava), a jedan je bolesnik preminuo.
Of the 29 patients described above that were treated in Study CAC-002-01 A total of 3patients discontinued (all due to AEs), and one patient died.
Od 29 prethodno opisanih bolesnika koji su liječeni u sklopu ispitivanja CAC-002-01, 3 bolesnika prekinulo je ispitivanje (svi zbog nuspojava), a jedan je bolesnik preminuo.
Of the 3 cases consistent with LSCD, one case reported a positive dechallenge and no other concomitant drugs or comorbidity.
U jednom od ta 3 slučaja koja su odgovarala LSCD-u zabilježeno je povlačenje nuspojave nakon prekida primjene lijeka (engl. positive dechallenge) bez istovremenog uzimanja drugih lijekova ili istovremeno prisutnih bolesti.
Of the 3 patients with significant pulmonary involvement at screening/baseline (percentage predicted forced vital capacity in the sitting position ranging from 58-67%), two demonstrated clinically meaningful improvements in FVC (+11.5% and +16.0%) in the sitting position by Week 26.
Od 3 bolesnika u kojih su na probiru/početku ispitivanja pluća bila znatno zahvaćena (postotak predviđenog forsiranog vitalnog kapaciteta u sjedećem položaju kretao se u rasponu od 58-67%) u 2 su primijećena klinički značajna poboljšanja FVC-a (+11,5% i +16,0%) u sjedećem položaju do 26. tjedna liječenja.
Of the 3,866 patients enrolled in these placebo-controlled studies, 64 % had received prior systemic therapy (biologic, conventional systemic or psoralen and ultraviolet A (PUVA)), 43.5 % had received prior phototherapy, 49.3 % had received prior conventional systemic therapy, and 26.4 % had received prior biologic therapy for the treatment of psoriasis.
Od 3866 bolesnika uključenih u ta placebom kontrolirana ispitivanja, njih 64% prethodno je za liječenje psorijaze primalo sistemsku terapiju (biološku terapiju, konvencionalnu sistemsku terapiju ili terapiju psoralenom i ultraljubičastim A zrakama [PUVA]), 43,5% ih je prethodno primalo fototerapiju, 49,3% konvencionalnu sistemsku terapiju, a 26,4% biološku terapiju.
Of the 306 previously treated patients enrolled in the study, 107 had melanoma and received nivolumab at a dose of 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg for a maximum of 2 years.
306 prethodno liječenih bolesnika uključenih u ispitivanje, njih 107 imalo je melanom te je primalo nivolumab u dozi od 0,1 mg/kg, 0,3 mg/kg, 1 mg/kg, 3 mg/kg ili 10 mg/kg tijekom najviše 2 godine.
Of the 32 inhibitor cases of the full patient cohort (n=101), 16 (16%) were classified as high titre (≥ 5 BU/mL) and 16 (16%) as low titre (< 5 BU/mL).
Od 32 bolesnika koji su razvili inhibitore od ukupne kohorte bolesnika (n = 101), 16 (16%) ih je bilo klasificirano kao visoki titar (≥ 5 BU/ml), a 16 (16%) kao niski titar (< 5 BU/ml).
Of the 326 (38%) patients with reports of adverse reactions of thrombocytopenia, 29 (9%) patients discontinued treatment with bosutinib due to thrombocytopenia.
Od 326 (38%) bolesnika s prijavljenim nuspojavama trombocitopenije, 29 (9%) bolesnika prekinulo je liječenje bosutinibom zbog trombocitopenije.
Of the 333 patients with ovarian cancer who received trabectedin in combination with PLD, 24% were 65 years of age or older and 6% were over 75 years.
Od 333 bolesnice s rakom jajnika koje su primale trabektedin u kombinaciji s PLD-om, 24 % je imalo 65 godina ili više, a 6 % je bilo starije od 75 godina.
Of the 35 cases where medical history was provided, in 25 there was a history of bronchoconstrictive disease (asthma, COPD or bronchospasm) and in 10 there was no documented history of bronchoconstrictive disease, including 3 cases where the reporter explicitly stated that there was no history of asthma/bronchospasm/COPD.
Od 35 slučajeva u kojima je dostavljena anamneza, u 25 slučajeva je postojala bronhokonstriktivna bolest (astma, KOBP ili bronhospazam) u anamnezi, a u 10 slučajeva nije bilo dokumentirane bronhokonstriktivne bolesti u anamnezi, uključujući 3 slučaja u kojima je izvjestitelj izričito naveo da nije bilo astme/bronhospazma/KOBP-a u anamnezi.
Of the 35 patients included in the efficacy analysis, 85.7% (95% CI: 69.7, 95.2) had a treatment response to XGEVA.
Od 35 bolesnika koji su bili uključeni u analizu djelotvornosti, kod 85,7% ( 95% CI: 69,7, 95,2) zabilježen je terapijski odgovor na lijek XGEVA.
Of the 35 patients with MCD in Study 2, 19 patients continued to be treated with siltuximab in the extension study, either at 11 mg/kg every 3 weeks (n = 11) or at 11 mg/kg every 6 weeks (n = 8), and all continued to have disease control after a median follow-up of 5 years (range 3.4-7.2 years).
Od 35 bolesnika s MCD-om u Ispitivanju 2, 19 bolesnika nastavilo je liječenje siltuksimabom u produžetku ispitivanja, bilo s 11 mg/kg svaka 3 tjedna (n = 11) ili s 11 mg/kg svakih 6 tjedana (n = 8), te je kod svih bolest kontrolirana nakon medijana praćenja od 5 godina (raspon 3,4-7,2 godina).
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re- treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4).
Među 361 ženom koja je liječena atosibanom u ispitivanjima faze III, 73 su primile najmanje jedno ponovno liječenje, 8 je primilo najmanje 2 ponovna liječenja, dok su 2 primile najmanje 3 ponovna liječenja (vidjeti dio 4.4).
Of the 39 patients who had received two or more prior induction regimens, 5 (13 %) [95 % CI: 4 %– 27 %] achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts) and 9 (23 %) [95 % CI: 11 %–39 %] achieved complete responses with or without full haematological recovery.
Od 39 bolesnika koji su prethodno prošli dva ili više indukcijska terapijska protokola, u 5 (13%) [95%-ni CI: 4%-27%] postignut je potpuni odgovor (broj blasta u koštanoj srži ≤ 5%, izostanak bilo kakvih pokazatelja bolesti, te potpuni oporavak svih staničnih loza u perifernoj krvi), dok je u njih 9 (23%) [95%-ni CI: 11%-39%] postignut potpuni odgovor s ili bez oporavka krvne slike.
Of the 39 placebo subjects, 29 completed 24 months of treatment with Revestive.
Od 39 ispitanika koji su primali placebo, 29 je završilo 24-mjesečno liječenje lijekom Revestive.
Of the 392 patients randomised, 76.3% were naïve to prior VEGF/VEGFR-targeted therapies, 49.0% were female, 49.7% were European, and the median age was 63 years.
392 randomizirana bolesnika, 76,3% prethodno nikad nije primalo terapije usmjerene na VEGF/VEGFR, 49,0% bile su žene, 49,7% bili su Europljani, a medijan dobi je iznosio 63 godine.
Of the 4,204 plaque psoriasis patients exposed to Taltz in clinical studies, a total of 301 were 65 years of age or older and 36 patients were 75 years of age or older.
Od 4204 bolesnika s plak psorijazom izložena lijeku Taltz u kliničkim ispitivanjima, ukupno je 301 bolesnik imao 65 ili više godina, dok je 36 bolesnika imalo 75 ili više godina.
Of the 4009 patients in this population, 3577 received treatment for at least 6 months, 3296 for at least one year, 2806 received treatment for at least 2 years and 1222 for 3 years.
Od 4009 bolesnika u toj populaciji, njih 3577 liječeno je najmanje 6 mjeseci, 3296 najmanje jednu godinu, 2806 liječeno je najmanje 2 godine, a 1222 tri godine.
Of the 403 patients who received CRESEMBA in the Phase 3 studies, 79 (20%) of patients had an estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2.
Od 403 bolesnika koji su primali lijek CRESEMBA u ispitivanjima faze 3, kod njih 79 (20%) procijenjena stopa glomerularne filtracije (GFR) bila je niţa od 60 mL/min/1,73 m2.